Lipfendra (enlicitide), a once-daily cholesterol tablet from Merck, is the first oral PCSK9 inhibitor approved by the US Food and Drug Administration. The FDA cleared it in July 2026 to lower LDL cholesterol in adults. In Europe the drug is still under review by the European Medicines Agency, and it is not available in Ireland.
Merck is known as MSD outside the United States and Canada, so any European or Irish launch would be under the MSD name. The company runs eight sites in Ireland, but no official source says where Lipfendra is made. Outcome data showing whether the pill cuts heart attacks or strokes are not expected for several years.
- US approval: 15 July 2026 on the FDA's novel drug approvals list; Merck announced it on 16 July 2026.
- Product: Lipfendra (enlicitide) 20 mg film-coated tablet, taken once a day on an empty stomach. Merck styles the brand LIPFENDRA.
- Use: with diet and exercise to lower LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH).
- Trial results: placebo-adjusted LDL cholesterol falls of 56% and 59% at week 24 in two Phase 3 trials with 3,207 patients in total.
- Not yet known: whether it reduces heart attacks, strokes or deaths. The CORALreef Outcomes trial is still running.
- Europe: enlicitide is on the EMA's list of medicines under evaluation. No Irish reimbursement assessment has started.
1. What the FDA approved
The FDA lists Lipfendra, with the active ingredient enlicitide decanoate, as novel drug approval number 26 of 2026, dated 15 July 2026, "to reduce low-density lipoprotein cholesterol". Merck's own announcement followed on 16 July. It says the tablet is approved as an adjunct to diet and exercise to reduce LDL cholesterol, often called bad cholesterol, in adults with hypercholesterolaemia, including those with the inherited form known as HeFH.
On 19 December 2025, the FDA awarded enlicitide a voucher under the Commissioner's National Priority Voucher pilot programme, a scheme that aims to speed up reviews of selected medicines. The FDA said it chose the drug for its potential to increase access through affordability. The US price has not been confirmed in an official source we reviewed.
Enlicitide is a macrocyclic peptide, a ring-shaped molecule designed to be absorbed from the gut. It binds to PCSK9, a protein that breaks down the LDL receptors the liver uses to clear cholesterol from the blood. Blocking PCSK9 leaves more receptors in place, so more LDL is removed. The US prescribing information says patients should take one 20 mg tablet each morning with water, black coffee or plain tea, swallow it whole, and wait at least 30 minutes before eating or drinking anything else. The label lists no contraindications.
2. The CORALreef trial results
The approval rests on two Phase 3 trials from Merck's CORALreef programme. Both enrolled adults who needed more LDL lowering despite stable treatment with moderate or high intensity statins, unless they could not tolerate statins.
| Measure | CORALreef Lipids | CORALreef HeFH |
|---|---|---|
| Patients randomised | 2,904 (1,935 enlicitide, 969 placebo) | 303 (202 enlicitide, 101 placebo) |
| LDL cholesterol vs placebo | minus 56% | minus 59% |
| Non-HDL cholesterol from baseline | minus 54% | minus 52% |
| ApoB from baseline | minus 50% | minus 48% |
| Trial registration | NCT05952856 | NCT05952869 |
Merck also reports a post-hoc figure of 60% for CORALreef Lipids, after LDL values at or below zero were removed under revised data handling rules. The pre-specified result is the 56% placebo-adjusted fall shown above.
On safety, side effects in CORALreef Lipids were reported at similar rates with enlicitide and placebo. In CORALreef HeFH, diarrhoea (7% vs 2%) and dizziness (9% vs 4%) were more common with the drug. In both trials, similar shares of patients on enlicitide and placebo stopped treatment because of side effects.
3. What the approval does not show yet
Both pivotal trials measured cholesterol, not clinical events. Merck states plainly that "it is not yet known" whether Lipfendra reduces cardiovascular illness or death. That question is being tested in CORALreef Outcomes (NCT06008756), which Merck says has finished enrolling more than 14,500 participants. The ClinicalTrials.gov record gives an estimated primary completion date of November 2029.
The wider CORALreef programme covers more than 19,000 people. It also includes an open-label extension study, a trial in children and teenagers with HeFH, and a combination study.
4. Where enlicitide stands in Europe
The EMA's monthly list of applications for new human medicines under evaluation, with data extracted on 5 October 2026, includes two entries for enlicitide. Both summarise the claimed use as treatment of "adults with primary hypercholesterolaemia or mixed dyslipidaemia".
- EMEA/H/C/006815: evaluation started on 26 March 2026 and restarted on 14 September 2026, after the applicant answered the CHMP's list of questions.
- EMEA/H/C/007131: evaluation started on 15 September 2026.
The EMA list does not name applicants and does not explain the second entry. It does note that where several applications cover the same substance, each gets its own row. Neither entry is flagged for accelerated assessment. EMA has not issued a CHMP opinion, so there is no EU marketing authorisation. A European brand name, if different from Lipfendra, has not been disclosed. EMA records also show an agreed paediatric investigation plan for enlicitide, held by Merck Sharp & Dohme B.V., which was last modified in March 2025.
5. The Irish angle
MSD Ireland says it has more than 4,200 employees across eight locations: Ballydine in Co Tipperary, Brinny in Co Cork, Carlow, Dunboyne in Co Meath, Dundalk in Co Louth, and Dublin, where it runs MSD Biotech, its Red Oak North head office and an animal health site in Blackrock. The company says it has been in Ireland for 50 years and describes Ballydine as its primary small molecule pipeline commercialisation facility globally. MSD has not said whether any Irish site makes enlicitide, and the US label names only Merck Sharp & Dohme LLC as the company it is manufactured for. Our MSD Ireland company page tracks the group's Irish news and trials.
No CORALreef trial lists a site in Ireland on ClinicalTrials.gov. The outcomes trial does include about 180 sites in EU countries, among them Germany, the Netherlands, Poland and Spain. Our enlicitide trials page lists the registered studies.
For Irish patients, the route runs through the EMA first. After an EU authorisation, a company seeking public reimbursement applies to the HSE, which can ask the National Centre for Pharmacoeconomics (NCPE) to assess cost-effectiveness. A search of the NCPE website on 2 November 2026 returned no entry for enlicitide or Lipfendra, so no Irish assessment has started.
Injectable treatments that target PCSK9 are already authorised in the EU: the antibodies evolocumab (Repatha) and alirocumab (Praluent), and inclisiran (Leqvio), a twice-yearly injection that reduces production of the protein. When the NCPE assessed inclisiran in March 2022, it recommended that it not be reimbursed unless its cost-effectiveness could be improved. See our PCSK9 inhibitors overview for how the existing medicines compare.
Frequently Asked Questions
Is Lipfendra available in Ireland?
No. It is approved only in the United States. Enlicitide is under review by the EMA, and an EU authorisation, followed by an HSE reimbursement decision, would be needed before it could be routinely prescribed here. Anyone with questions about their cholesterol treatment should speak to their doctor.
How is it different from existing PCSK9 medicines?
Evolocumab, alirocumab and inclisiran are given by injection. Enlicitide is a daily tablet. Unlike evolocumab and alirocumab, it does not yet have outcome trial data showing a reduction in heart attacks or strokes.
Is it made in Ireland?
Not disclosed. MSD operates several manufacturing sites in Ireland, but neither MSD nor the FDA has said where Lipfendra is produced.
Outlook
The next milestone for European patients is a CHMP opinion on enlicitide, followed by a European Commission decision. After that, watch for an HSE reimbursement application and an NCPE assessment. The bigger test is CORALreef Outcomes, which will show whether lower LDL cholesterol from a daily pill turns into fewer heart attacks and strokes.
Sources
- Merck, Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia, 16 July 2026
- US Food and Drug Administration, Novel Drug Approvals for 2026, accessed 2 November 2026
- US Food and Drug Administration, FDA Grants Two National Priority Vouchers, 19 December 2025
- Merck, Lipfendra US Prescribing Information, revised July 2026
- European Medicines Agency, Applications for new human medicines under evaluation, October 2026, data extracted 5 October 2026
- European Medicines Agency, Paediatric investigation plan EMA/PE/0000228536: enlicitide, decision 19 March 2025
- ClinicalTrials.gov, NCT05952856, NCT05952869 and NCT06008756, accessed 2 November 2026
- MSD Ireland, MSD Ireland: An Overview and Our Sites, accessed 2 November 2026
- National Centre for Pharmacoeconomics, Inclisiran (Leqvio), HTA ID 20051, 23 March 2022
Cover image: AI-generated illustration of the Lipfendra carton and tablets. It is not a photograph of the real product or its packaging.
